Sol-Gel Technologies Ltd.

Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome Top-line results remain on track for late November 2026 NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.

Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 Sol-Gel has initiated a proof-of-concept study in High-frequency BCC (HF-BCC) Sol-Gel initiated a study evaluating topical

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist

NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the “Shares”) at a price of $72.00 per Share, resulting in gross proceeds to the Company, before

NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.  (NASDAQ: SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”).

NESS ZIONA, Israel , Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.  (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update following the unblinding of clinical data from its vehicle-controlled

Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential In September 2025 , Sol-Gel announced Health Canada approval of EPSOLAY Sol-Gel signed an additional agreement with

NESS ZIONA, Israel , Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.  (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double

Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026 Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoing Sol-Gel and Mayne Pharma Announce the Purchase

NESS ZIONA, Israel , May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd . (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March   31 st , 2025 Total revenue